INTRODUCTION
Psychiatric disorders, including depression, psychosis, and bipolar disorder, are common and gaining more acceptance in the United States. The most commonly used classes of medications for these disorders are antidepressants, antipsychotics, and lithium. Unfortunately, these medications are associated with signifi cant neurotoxicities.
ANTIDEPRESSANTS
In the period between 1999 and 2002, 8% of the adult population in the United States reported using an antidepressant. The rate of use was quite different between females (10.6%) and males (5.2%).
1 The classes of antidepressants available include monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), serotonin-specifi c reuptake inhibitors (SSRIs), and newer compounds designed to increase serotonin, norepinephrine, dopamine, or a combination of these (Table 1) . Some neurotoxicities such as antidepressant discontinuation syndrome, serotonin syndrome, and poisoning are common to all antidepressants. Other neurological adverse effects are specifi c to certain medications.
An adverse effect surveillance system in psychiatric hospitals in Germany, Austria, and Switzerland studied severe adverse effects of antidepressants in 122,562 patients.
2
Neurological adverse effects occurred in approximately 0.11% of patients receiving TCAs alone, in about 0.06% of patients receiving SSRIs alone, and in about 0.04% of those receiving only mirtazapine, mianserin, venlafaxine, nefazodone, or reboxetine. The type of neurological effects differed among antidepressant classes: for TCAs, delirium and seizures were most common; for SSRIs, serotonin syndrome was most common; and for the other medications, delirium and seizures were most common.
2 Depression is particularly common in patients with epilepsy, with a 20% to 55% prevalence rate and a suicide risk of three to fi ve times that of the worldwide population.
3 Therefore, patients with epilepsy often require antidepressant treatment. However, most antidepressants have been reported to induce seizures. The risk is different for each class of medications and is discussed in more detail later.
Antidepressant Discontinuation Syndrome
Antidepressant discontinuation syndrome, sometimes called SSRI discontinuation syndrome, may occur in up to 30% of patients who abruptly discontinue antidepressants. It is more common in patients treated with antidepressants with shorter half-lives (see Table 1 ). In one
